US equities
|
SPCX
$167.23
▲+5.20%
NVDA
$236.28
▲+1.00%
MU
$1,066.89
▼-0.74%
TSLA
$378.37
▲+2.10%
MSFT
$526.43
▲+1.72%
SNDK
$1,710.22
▼-0.57%
INTC
$117.08
▼-1.89%
META
$744.20
▲+2.21%
SPCX
$167.23
▲+5.20%
NVDA
$236.28
▲+1.00%
MU
$1,066.89
▼-0.74%
TSLA
$378.37
▲+2.10%
MSFT
$526.43
▲+1.72%
SNDK
$1,710.22
▼-0.57%
INTC
$117.08
▼-1.89%
META
$744.20
▲+2.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
41.73
+0.34 (+0.81%)
Delayed Quote
Updated: 12:48 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
URGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
June 05, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
June 03, 2025
From
Rosen Law Firm, P.A.
Via
Business Wire
UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors With Large Losses in UroGen Pharma Ltd. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
June 03, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action
June 03, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. and Encourages Investors to Contact the Firm
June 02, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
June 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
June 02, 2025
From
Law Offices of Howard G. Smith
Via
Business Wire
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
June 02, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
June 02, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 31, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors
May 30, 2025
From
Kirby McInerney LLP
Via
Business Wire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.
May 30, 2025
From
Robbins LLP
Via
GlobeNewswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
May 30, 2025
From
The Schall Law Firm
Via
Business Wire
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)
May 30, 2025
From
Bleichmar Fonti & Auld LLP
Via
Business Wire
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
May 30, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
May 29, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action
May 29, 2025
From
Law Offices of Howard G. Smith
Via
Business Wire
URGN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against UroGen Pharma Ltd.
May 29, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
URGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of UroGen Pharma Ltd. Investors
May 29, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
May 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 27, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
↗
May 25, 2025
Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.
Via
Benzinga
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
May 24, 2025
Via
NewMediaWire
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
May 24, 2025
Via
TheNewswire.com
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
May 23, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
May 23, 2025
Via
TheNewswire.com
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
May 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
May 22, 2025
Via
TheNewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
May 22, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
